Two experimental drug molecules promoted myelin repair in MS disease models, pointing toward a possible future route for ...

Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions ...

Multiple sclerosis (MS) is most prevalent in Northern Europe and Canada, and more common in the northernmost latitudes. In ...

A new study by researchers in the Department of Clinical Neuroscience, Karolinska Institutet, has identified 18 potential drug targets for the treatment of multiple sclerosis. The study may pave the ...

Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions ...

Swiss pharmaceuticals powerhouse Roche announced on Saturday that the company’s experimental multiple sclerosis drug met its primary goal in a late-stage trial in patients with a rare form of the ...

Miniature brain models (organoids) help evaluate treatments for myelin damage in multiple sclerosis. These human-derived ...

BARCELONA, Spain — Annual dosing of rituximab for relapsing-remitting multiple sclerosis (RRMS) was noninferior to the typical dosing schedule of once every 6 months, which could offer a more ...

An investigational drug for multiple sclerosis from Io Therapeutics has restored leg mobility and myelin nerve coatings in mice, the biotech announced Dec. 23. The Texas-based company conducted the ...

Sanofi said a U.S. regulatory decision on its tolebrutinib experimental treatment for a type of multiple sclerosis would be delayed again, and that a late-stage trial for a different form of the ...

Roche Holding said a drug candidate for multiple sclerosis met the primary goal in a late-stage clinical trial for the most common form of the disease. The Swiss pharmaceutical company said Monday ...